

JAMP Teriflunomide

Reference product AUBAGIO®



Pill shown is not actual size

Therapeutic use	Immunomodulating agent	
Indication¹	Indicated for monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.	
Active ingredient	Teriflunomide	
Dosage strength	14 mg	
DIN	02504170	02504170
Supplied	28 count blisters	84 count blisters
Storage and handling	Store at 15°C to 30°C. For blister card wallet, remove tablet only when ready to use. JAMP Teriflunomide must be kept out of the reach and sight of children.	
Shelf life	36 M	

Consult the Product Monograph at www.jampinfo.com for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-399-9091 Option 2

This document contains information only for residents of Canada. Please be aware that JAMP PHARM CORPORATION assumes no responsibility for access to and use of such information which may not comply with legal restrictions, regulations, registrations or intended use in the country if your origin. Eligibility restrictions and other terms and conditions may apply.

Reference: 1. JAMP Teriflunomide Product Monograph. JAMP Pharma Corporation, February 3, 2022.

The JAMP Care™ Patient Support Program

Provides the following benefits to your patients taking

JAMP Teriflunomide



Reimbursement navigation



Bridging (as per provincial regulations)



Financial assistance (as per provincial regulations)



PLUS

Nurse Single Point of Contact Service



Blood/Laboratory Work & Services including Accelerated Elimination Process



Personalized consultation with a nutritionist (available on demand)

JAMP Teriflunomide	JAMP Care™	Other Programs
Reimbursement navigation	✓	✓
Bridging	✓	✓
Financial assistance	✓	✓
Nurse (available on demand)	✓	
Blood/laboratory work & coordination	✓	✓
Lab work/accelerated elimination procedure	✓	✓
Personalized consultation with nutritionist (available on demand)	✓	
Patient education materials	✓	✓

*Terms and conditions apply

For more information on the JAMP Care Patient Support Program



Call toll-free: **1-866-417-8084**
Fax: **1-844-222-4819**
Monday to Friday, 8am to 8pm EST



Email: support@jampcarepsp.ca



Visit: www.jampcare-support.ca

For specific questions about JAMP Teriflunomide



Call the JAMP Pharma Group Medical Information Department at 1-866-399-9091 Option 2



Email: medinfo@jamppharma.com

Consult the Product Monograph at www.jampinfo.com for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-399-9091 Option 2

Reference: 1. JAMP Teriflunomide Product Monograph. JAMP Pharma Corporation, February 3, 2022.